InterPAD - DETAILS

diosmin, 520-27-4, Barosmin, Diosimin, Flebosten, Venosmine, Diosmil, Diosmine, Daflon, Tovene, Ven-Detrex, Diovenor, Buchu Resin, Litosmil, Veno-V, flebosmil, Diosminum, Rioven, Diosmetin 7-O-rutinoside, Diosven, Flebaven, Flebavena, Hemerven, Insuven, Varinon, Dioven, Diosmetin 7-rutinoside, UNII-7QM776WJ5N, Diosmin [INN], 7QM776WJ5N, CCRIS 7915, CHEBI:4631, DTXSID4045892, Diosmetin-7-O-rutinoside, EINECS 208-289-7, NSC-758417, 3',5,7-trihydroxy-4'-methoxyflavone-7-rutinoside, SE 4601, 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one, DTXCID2025892, 3',5,7-Trihydroxy-4'-methoxyflavone 7-rutinoside, Diosmin (INN), MFCD00009772, NSC 758417, 3',5,7-trihydroxy-4'-methoxyflavone 7-rhamnoglucoside, 3',5,7-Trihydroxy-4'-methoxyflavone-7-(6-O-(-deoxy-alpha-L-mannopyraonsyl)-beta-D-glucopyranoside, 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one, 3',5-Dihydroxy-4'-methoxy-4-oxo-4H-chromen-7-ylrutosid, DIOSMIN (MART.), DIOSMIN [MART.], DIOSMIN (USP-RS), DIOSMIN [USP-RS], Diosmin, analytical standard, 4H-1-Benzopyran-4-one, 7-((6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl)oxy)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-, 4H-1-Benzopyran-4-one,7-[[6-O-(6-deoxy-a-L-mannopyranosyl)-b-D-glucopyranosyl]oxy]-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-, 5-hydroxy-2-(3-hydroxy-4-methoxy-phenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-2-yl]oxy-chromen-4-one, 5-Hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-((6-O-alpha-L-rhamnopyranosyl-beta-D-glycopyranosyl)oxy)-4-chromenon, DIOSMIN (EP MONOGRAPH), DIOSMIN [EP MONOGRAPH], 3',5-Dihydroxy-4'-methoxy-4-oxo-4H-chromen-7-ylrutosid [IUPAC], Resin, Buchu, 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-oxo-4H-1-benzopyran-7-yl 6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranoside, 7-((6-O-(6-Deoxy-ga-L-mannopyranosyl)-beta-D-glucopyranosyl)oxy)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one, CAS-520-27-4, Diosmin [INN:BAN], Diosmin [INN-Spanish], Diosmine [INN-French], Diosminum [INN-Latin], SR-01000799147, Diosmina, 3',5-Dihydroxy-4'-methoxy-4-oxo-4H-chromen-7-ylrutosid (IUPAC), NCGC00095022-01, 4H-1-Benzopyran-4-one, 7-((6-O-(6-deoxy-.alpha.-L-mannopyranosyl)-.beta.-D-glucopyranosyl)oxy)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-, 4H-1-Benzopyran-4-one, 7-[[6-O-(6-deoxy-.alpha.-L-mannopyranosyl)-.beta.-D-glucopyranosyl]oxy]-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-, Daflon (TN), Diosmin (8), DIOSMIN [DSC], DIOSMIN [MI], DIOSMIN [WHO-DD], MLS001304032, SCHEMBL120870, CHEMBL231884, C05CA03, BDBM153267, GLXC-13353, HMS2233P16, HMS3713L08, Tox21_111392, s2292, AKOS015969767, Tox21_111392_1, BCP9000612, CCG-208570, DB08995, SMP1_000183, NCGC00344564-01, AS-13224, BP-12422, SMR000718616, BCP0726000067, NS00005135, C10039, D07858, EN300-18388399, 3',5,7-trihydroxy-4'-methoxy flavone-7-rutinoside, Q2607865, SR-01000799147-4, SR-01000799147-5, SR-01000799147-6, Diosmin, European Pharmacopoeia (EP) Reference Standard, Diosmin, United States Pharmacopeia (USP) Reference Standard, Diosmin for system suitability, European Pharmacopoeia (EP) Reference Standard, 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)methyl)tetrahydro-2H-pyran-2-yloxy)-4H-chromen-4-one, 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-(O6-alpha-L-rhamnopyranosyl-beta-D-glucopyranosyloxy)chromen-4-one, 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one, 5-HYDROXY-2-(3-HYDROXY-4-METHOXYPHENYL)-7-{[(2S,3R,4S,5S,6R)-3,4,5-TRIHYDROXY-6-({[(2R,3R,4R,5R,6S)-3,4,5-TRIHYDROXY-6-METHYLOXAN-2-YL]OXY}METHYL)OXAN-2-YL]OXY}-4H-CHROMEN-4-ONE, 7-((6-O-(6-DEOXY-GA-L-MANNOPYRANOSYL)-.BETA.-D-GLUCOPYRANOSYL)OXY)-5-HYDROXY-2-(3-HYDROXY-4-METHOXYPHENYL)-4H-1-BENZOPYRAN-4-ONE

Name	Diosmin
PubChem CID	5281613
Molecular Weight	608.5g/mol
Synonyms	diosmin, 520-27-4, Barosmin, Diosimin, Flebosten, Venosmine, Diosmil, Diosmine, Daflon, Tovene, Ven-Detrex, Diovenor, Buchu Resin, Litosmil, Veno-V, flebosmil, Diosminum, Rioven, Diosmetin 7-O-rutinoside, Diosven, Flebaven, Flebavena, Hemerven, Insuven, Varinon, Dioven, Diosmetin 7-rutinoside, UNII-7QM776WJ5N, Diosmin [INN], 7QM776WJ5N, CCRIS 7915, CHEBI:4631, DTXSID4045892, Diosmetin-7-O-rutinoside, EINECS 208-289-7, NSC-758417, 3',5,7-trihydroxy-4'-methoxyflavone-7-rutinoside, SE 4601, 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one, DTXCID2025892, 3',5,7-Trihydroxy-4'-methoxyflavone 7-rutinoside, Diosmin (INN), MFCD00009772, NSC 758417, 3',5,7-trihydroxy-4'-methoxyflavone 7-rhamnoglucoside, 3',5,7-Trihydroxy-4'-methoxyflavone-7-(6-O-(-deoxy-alpha-L-mannopyraonsyl)-beta-D-glucopyranoside, 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one, 3',5-Dihydroxy-4'-methoxy-4-oxo-4H-chromen-7-ylrutosid, DIOSMIN (MART.), DIOSMIN [MART.], DIOSMIN (USP-RS), DIOSMIN [USP-RS], Diosmin, analytical standard, 4H-1-Benzopyran-4-one, 7-((6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl)oxy)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-, 4H-1-Benzopyran-4-one,7-[[6-O-(6-deoxy-a-L-mannopyranosyl)-b-D-glucopyranosyl]oxy]-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-, 5-hydroxy-2-(3-hydroxy-4-methoxy-phenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-2-yl]oxy-chromen-4-one, 5-Hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-((6-O-alpha-L-rhamnopyranosyl-beta-D-glycopyranosyl)oxy)-4-chromenon, DIOSMIN (EP MONOGRAPH), DIOSMIN [EP MONOGRAPH], 3',5-Dihydroxy-4'-methoxy-4-oxo-4H-chromen-7-ylrutosid [IUPAC], Resin, Buchu, 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-oxo-4H-1-benzopyran-7-yl 6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranoside, 7-((6-O-(6-Deoxy-ga-L-mannopyranosyl)-beta-D-glucopyranosyl)oxy)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one, CAS-520-27-4, Diosmin [INN:BAN], Diosmin [INN-Spanish], Diosmine [INN-French], Diosminum [INN-Latin], SR-01000799147, Diosmina, 3',5-Dihydroxy-4'-methoxy-4-oxo-4H-chromen-7-ylrutosid (IUPAC), NCGC00095022-01, 4H-1-Benzopyran-4-one, 7-((6-O-(6-deoxy-.alpha.-L-mannopyranosyl)-.beta.-D-glucopyranosyl)oxy)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-, 4H-1-Benzopyran-4-one, 7-[[6-O-(6-deoxy-.alpha.-L-mannopyranosyl)-.beta.-D-glucopyranosyl]oxy]-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-, Daflon (TN), Diosmin (8), DIOSMIN [DSC], DIOSMIN [MI], DIOSMIN [WHO-DD], MLS001304032, SCHEMBL120870, CHEMBL231884, C05CA03, BDBM153267, GLXC-13353, HMS2233P16, HMS3713L08, Tox21_111392, s2292, AKOS015969767, Tox21_111392_1, BCP9000612, CCG-208570, DB08995, SMP1_000183, NCGC00344564-01, AS-13224, BP-12422, SMR000718616, BCP0726000067, NS00005135, C10039, D07858, EN300-18388399, 3',5,7-trihydroxy-4'-methoxy flavone-7-rutinoside, Q2607865, SR-01000799147-4, SR-01000799147-5, SR-01000799147-6, Diosmin, European Pharmacopoeia (EP) Reference Standard, Diosmin, United States Pharmacopeia (USP) Reference Standard, Diosmin for system suitability, European Pharmacopoeia (EP) Reference Standard, 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)methyl)tetrahydro-2H-pyran-2-yloxy)-4H-chromen-4-one, 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-(O6-alpha-L-rhamnopyranosyl-beta-D-glucopyranosyloxy)chromen-4-one, 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one, 5-HYDROXY-2-(3-HYDROXY-4-METHOXYPHENYL)-7-{[(2S,3R,4S,5S,6R)-3,4,5-TRIHYDROXY-6-({[(2R,3R,4R,5R,6S)-3,4,5-TRIHYDROXY-6-METHYLOXAN-2-YL]OXY}METHYL)OXAN-2-YL]OXY}-4H-CHROMEN-4-ONE, 7-((6-O-(6-DEOXY-GA-L-MANNOPYRANOSYL)-.BETA.-D-GLUCOPYRANOSYL)OXY)-5-HYDROXY-2-(3-HYDROXY-4-METHOXYPHENYL)-4H-1-BENZOPYRAN-4-ONE
Drug Type	Small molecule
Formula	C₂₈H₃₂O₁₅
SMILES	CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=CC(=C4C(=C3)OC(=CC4=O)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O
InChI	1S/C28H32O15/c1-10-21(32)23(34)25(36)27(40-10)39-9-19-22(33)24(35)26(37)28(43-19)41-12-6-14(30)20-15(31)8-17(42-18(20)7-12)11-3-4-16(38-2)13(29)5-11/h3-8,10,19,21-30,32-37H,9H2,1-2H3/t10-,19+,21-,22+,23+,24-,25+,26+,27+,28+/m0/s1
InChIKey	GZSOSUNBTXMUFQ-YFAPSIMESA-N
CAS Number	520-27-4
ChEMBL ID	CHEMBL231884
ChEBI ID	CHEBI:4631
TTD ID	D0X9XP
Drug Bank ID	DB08995
KEGG ID	C10039
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Naringenin, Diosmin
Partner Name	Naringenin
Disease Info	[ICD-11: 2B90]	Colon cancer		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G0/G1 phase
Gene Regulation	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Expression	CASP3	hsa836
	Up-regulation	Expression	CASP8	hsa841
	Up-regulation	Expression	CASP9	hsa842
	Down-regulation	Expression	CHUK	hsa1147
	Down-regulation	Expression	IKBKB	hsa3551
	Down-regulation	Expression	NFKB1	hsa4790
	Up-regulation	Expression	TP53	hsa7157
In Vitro Model	HCT 116	Colon carcinoma	Homo sapiens (Human)	CVCL_0291
In Vitro Model	SW480	Colon adenocarcinoma	Homo sapiens (Human)	CVCL_0546
Result	Diosmin in combination with naringenin enhances apoptosis in colon cancer cells